-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Day One Biopharmaceutical, Lowers Price Target to $34

Benzinga·03/05/2025 14:57:57
Listen to the news
JP Morgan analyst Anupam Rama maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and lowers the price target from $39 to $34.